Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) will report its financial results for Q3 2020 and provide a corporate update on November 4, 2020, at 4:30 p.m. ET. Investors can access the live call at (877) 305-6769 (domestic) or (678) 562-4239 (international) with conference ID 5179918. A webcast will also be available on Otonomy's investor relations website.

The company focuses on innovative therapeutics for neurotology, particularly targeting conditions like Ménière’s disease and tinnitus through its unique drug delivery technology.

Positive

• Company emphasizes innovative therapeutics for neurotology, targeting unmet medical needs.
• Pioneering drug delivery technology offers potential for sustained drug exposure.

Negative

• None.

SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter of 2020 and provide a corporate update at 4:30 p.m. ET on November 4, 2020.

The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 5179918. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

When will Otonomy report its Q3 2020 financial results?

Otonomy will report its Q3 2020 financial results on November 4, 2020, at 4:30 p.m. ET.

How can I access the Otonomy earnings call?

You can access the earnings call by dialing (877) 305-6769 for domestic calls or (678) 562-4239 for international calls, using conference ID 5179918.

What is the focus of Otonomy's drug development?

Otonomy focuses on innovative therapeutics for neurotology, addressing conditions like Ménière’s disease, hearing loss, and tinnitus.

Where can I find the webcast of Otonomy's earnings call?

The webcast will be available on Otonomy's investor relations website and archived for 30 days.